A01 IHH acts as a tumor suppressor of lung adenocarcinoma by repressing reactive oxygen species. Sahba Kasiri, UT Southwestern Medical Center, Dallas, TX, USA.

A02 Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Michael Gillette, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

A03 Lung adenocarcinoma resident microbiome may contribute to cancer hypomethylation status. Erin Marshall, BC Cancer Research Centre, Vancouver, BC, Canada.


A05 ART1, a mono-ADP-ribosyltransferase, regulates tumor infiltrating CD8+ T cells and is highly expressed in EGFR mutated lung cancers. Sumit Mukherjee, Weill Cornell Medicine, New York, NY, USA.

A06 Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC. Robert Nichols, Revolution Medicines, Redwood City, CA, USA.

A07 The genomic landscape of SMARCA4 alterations and association with patient outcomes in lung cancer. Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A08 MYC-driven SCLC has unique metabolic vulnerabilities. Sarah Wait, Huntsman Cancer Institute, Salt Lake City, UT, USA.


A10 A novel inhibitor for KRASG12C mutant lung carcinoma. Misako Nagasaka, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.

A11 Blockade of myeloid suppressor cells overcomes the anti-PD-1/PD-L1 resistance in KRAS-driven and LKB1-deficient NSCLC. Rui Li, UCLA, Los Angeles, CA, USA.


A14 Circulating ensembles of tumor-associated cells are ubiquitous in lung cancers. Dadasaheb Akolkar, Datar Cancer Genetics Limited, Nasik, Maharashtra, India.

A15 Cancer-associated mesenchymal cells influence lung cancer metastatic phenotypes in vitro and in vivo. Levi Beverly, University of Louisville, Louisville, KY.

A16 Autoantibody-antigen complexes can detect limited-stage small-cell lung cancer. Kristin Lastwika, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

A17 Inhibition of RUVBL1/2 ATPase activity drives immune infiltration and radiosensitizes non-small cell lung cancer. Paul Yenerall, UT Southwestern Medical Center, Dallas, TX, USA.

A18 Culture of immortalized human alveolar epithelial cells in 2D and 3D to model lung adenocarcinoma progression in vitro. Ite Offringa, University of Southern California, Los Angeles, CA, USA.

A19 Epithelial beta 1 integrin regulates lung cancer susceptibility through NF-kB signaling. Erin Plosa, Vanderbilt University Medical Center, Nashville, TN, USA.


A21 Targeting glucose reliance in lung squamous cell carcinoma. Jung-whan Kim, University of Texas at Dallas, Richardson, TX, USA.

A22 Integrated proteometabolomic analysis reveals metabolic vulnerabilities in small-cell lung cancer. Antony Prabhu, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

A23 A genomically adjusted clinicopathologic model predicts recurrence in resected early-stage lung squamous cell carcinoma. James Connolly, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

A25 PTPRH mutations in NSCLC regulate EGFR phosphorylation. Matthew Swiatnicki, Michigan State University, East Lansing, MI, USA.

A26 Deciphering the functional redundancy of USP4 and USP15. Sarah Zachariah, Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

A27 Stage I lung adenocarcinoma gene expression associated with aggressive histologic features for guiding precision surgery and therapy. Jiarui Zhang, Boston University School of Medicine, Boston, MA, USA.

A28 Investigating antitumor T-cell responses using NINJA: An inducible genetic model for creating neoantigens. Brittany Fitzgerald, Yale University School of Medicine, New Haven, CT, USA.

A29 Immune suppressive microenvironment induced by increased Treg during EGFR-TKI mediated IP-10 and TGF-β. Sook-hee Hong, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

A30 Tumor-infiltrating lymphocytes (TILs) found elevated in lung adenocarcinomas (LUAD) using automated digital pathology masks derived from deep-learning models. Mustafa Jaber, NantOomics, Culver City, CA, USA.

A31 A reservoir of tumor-specific CD8 T cells in lung cancer resides in the draining lymph node. Nikhil Joshi, Yale University, New Haven, CT.

A32 Evaluation of the mutant KRAS-driven NSCLC tumor immune microenvironment using patient-derived cell line xenografts in a humanized mouse preclinical model for development of new immunotherapy approaches. Huiyu Li, UT Southwestern Medical Center, Dallas, TX, USA.

A33 Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC. Bin Liu, UCLA, Los Angeles, CA, USA.

A34 Identification of Th1 epitopes in lung non-small cell lung cancer antigens to develop a multiantigen vaccine. Laura Riolobos, University of Washington, Seattle, WA, USA.

A35 Dendritic cell in situ vaccination potentiates anti-PD-1 efficacy and induces immunoediting in a murine model of NSCLC. Ramin Salehi-Rad, UCLA, Los Angeles, CA, USA.
A36 Patient-specific humanized PDX model for overcoming tumor resistance to immune checkpoint inhibitors in NSCLC patients. Ariel Sobarzo, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

A37 N-803 plus nivolumab for advanced or metastatic non-small cell lung cancer: Update on phase II experience of combination PD1 blockade with an IL-15 superagonist. John Wrangle, Medical University of South Carolina, Charleston, SC, USA.

A38 Gemcitabine improves suppressive immune microenvironment induced by long-term treatment with EGFR-TKIs: Implications for combination chemotherapy and immunotherapy. Xueqian Wu, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

A39 Reactive cutaneous capillary endothelial proliferation caused by camrelizumab (SHR-1210) through activation of HIF-1α/VEGF signaling pathway. Xueqian Wu, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

A40 Antioxidant, anti-inflammatory, and antiapoptotic potential of curcumin in benzo(a)pyrene (BaP)-induced lung injury in rats. Saleh Almatroodi, Qassim University, Buraydah, Qassim, Saudi Arabia.

A41 EO1001: A first-in-class irreversible pan-ErbB inhibitor with excellent brain penetration. Dennis Brown, Edison Oncology Holding Corp., Menlo Park, CA, USA.